GPC2 and neuroblastoma: This poses GPC2 as a promising immunotherapeutic target, with multiple groups showing anti-neuroblastoma activity in mice treated with CAR-T cells with no significant associated toxicities [25,28,29] and clinical trial underway [NCT05650749].